Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Heliosphere
Heliosphere May. 12 at 10:06 PM
$CMPX $RHHBY or $AMGN should buy $CMPX Both have been in angiogenesis field and understand these pathways well. Avastin has already lost most of its patents now. Could replace Avastin in most oncology indications and new indications/combinations!
1 · Reply
Quantumup
Quantumup May. 12 at 12:13 PM
H.C. Wainwright⬆️ $CLYM's PT to $20/said: We draw investors' attention to the fact that Climb Bio is poised to have a catalyst-rich year, with multiple clinical milestones slated for achievement with both lead assets from its portfolio. $RHHBY $VERA BIIB VRTX H.C. Wainwright added—Enrollment is ongoing in the PrisMN Phase 2 primary membranous nephropathy (pMN) trial of Climb Bio's most advanced asset, budoprutug. PrisMN is a global open-label, dose-ranging Phase 2 study designed to evaluate pharmacodynamics (including B cells, anti-PLA2R, and total immunoglobulin) and preliminary efficacy (including complete and partial remission) in pMN patients with persistent proteinuria despite optimized renin-angiotensin-aldosterone system (RAAS) inhibition, and to identify a dose for Phase 3 development. Initial data from this trial is anticipated in 4Q26. We reiterate our Buy rating, while raising our 12-month price target to $20 from the prior $15 per share.
0 · Reply
Woodman7
Woodman7 May. 11 at 11:41 PM
$ABT $BMY $RHHBY
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 11 at 1:59 PM
$KYTX 5. Partnership or strategic interest hints This is where the speculative fireworks will happen. Big Pharma is aggressively moving into autoimmune and cell therapy: • $RHHBY • $BMY • $ABBV • Novartis • $GILD The entire sector is watching autoimmune CAR-T closely. Kyverna recently strengthened commercial leadership hiring ahead of launch preparation. A bullish earnings call could hint at: • strategic partnership discussions • manufacturing collaborations • commercialization support • regional licensing • or even inbound acquisition interest Even subtle language will ignite biotech momentum. 💲🔥💲🔥💲
0 · Reply
biolover
biolover May. 11 at 1:59 PM
$RHHBY $VKTX Roche CEO in Oct
0 · Reply
biolover
biolover May. 11 at 1:21 PM
$VKTX $RHHBY not presenting their phase 2 at ADA ? I thought they said they would ? They left us confused on what caused the gap between treatment and efficacy estimands ? Poor tolerability ? Or placebo switching to SOC. I understand not showing tolerability numbers. But why not showing placebo performance. ? Also no presentation from $AMGN Amgen still top obesity M&A candidate. They stated before “ all in “ although I sense different all in from $PFE Bourla”s
0 · Reply
hegdaom
hegdaom May. 10 at 4:49 AM
$CAPR An early win here legally and an approval creates a strong pathway to a $10 billion valuation with $RHHBY & $PFE as acquirers. $XBB $XBI
0 · Reply
BioRich
BioRich May. 7 at 11:55 AM
$ALT Here's one to spark MASSIVE discussion... $RHHBY just bought PathAI.... $750M deal. Run with this $ALT Nation. Cheers! $XBI
0 · Reply
GreenEnergy7B
GreenEnergy7B May. 7 at 10:49 AM
$ALT GLP1/Obesity/MASH M&A is heating up. Who will buy ALT first in phs3? https://www.cnbc.com/2026/05/06/novo-nordisk-ceo-mike-doustdar-ozempic-maker-looking-for-deals.html $NVO $PFE $MRK $RHHBY
0 · Reply
LabPsycho
LabPsycho May. 6 at 3:05 PM
$MAIA I am going to keep posting my idea on how to 5X THIO's potential market value until someone takes the baton and runs with it. My antibody ADC-THIO construct shown below based on my computational chemistry and molecular dynamic simulations, and the hypothesis / plausibility is supported by several peer reviewed articles and my own creative, scientifically sound input. In my earlier posts I also describe quick, easy, cost effective pilot studies one could do in a lab in one day to evaluate feasibility. Come on $REGN or $RHHBY - see the light.
1 · Reply
Latest News on RHHBY
No data available.
Heliosphere
Heliosphere May. 12 at 10:06 PM
$CMPX $RHHBY or $AMGN should buy $CMPX Both have been in angiogenesis field and understand these pathways well. Avastin has already lost most of its patents now. Could replace Avastin in most oncology indications and new indications/combinations!
1 · Reply
Quantumup
Quantumup May. 12 at 12:13 PM
H.C. Wainwright⬆️ $CLYM's PT to $20/said: We draw investors' attention to the fact that Climb Bio is poised to have a catalyst-rich year, with multiple clinical milestones slated for achievement with both lead assets from its portfolio. $RHHBY $VERA BIIB VRTX H.C. Wainwright added—Enrollment is ongoing in the PrisMN Phase 2 primary membranous nephropathy (pMN) trial of Climb Bio's most advanced asset, budoprutug. PrisMN is a global open-label, dose-ranging Phase 2 study designed to evaluate pharmacodynamics (including B cells, anti-PLA2R, and total immunoglobulin) and preliminary efficacy (including complete and partial remission) in pMN patients with persistent proteinuria despite optimized renin-angiotensin-aldosterone system (RAAS) inhibition, and to identify a dose for Phase 3 development. Initial data from this trial is anticipated in 4Q26. We reiterate our Buy rating, while raising our 12-month price target to $20 from the prior $15 per share.
0 · Reply
Woodman7
Woodman7 May. 11 at 11:41 PM
$ABT $BMY $RHHBY
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 11 at 1:59 PM
$KYTX 5. Partnership or strategic interest hints This is where the speculative fireworks will happen. Big Pharma is aggressively moving into autoimmune and cell therapy: • $RHHBY • $BMY • $ABBV • Novartis • $GILD The entire sector is watching autoimmune CAR-T closely. Kyverna recently strengthened commercial leadership hiring ahead of launch preparation. A bullish earnings call could hint at: • strategic partnership discussions • manufacturing collaborations • commercialization support • regional licensing • or even inbound acquisition interest Even subtle language will ignite biotech momentum. 💲🔥💲🔥💲
0 · Reply
biolover
biolover May. 11 at 1:59 PM
$RHHBY $VKTX Roche CEO in Oct
0 · Reply
biolover
biolover May. 11 at 1:21 PM
$VKTX $RHHBY not presenting their phase 2 at ADA ? I thought they said they would ? They left us confused on what caused the gap between treatment and efficacy estimands ? Poor tolerability ? Or placebo switching to SOC. I understand not showing tolerability numbers. But why not showing placebo performance. ? Also no presentation from $AMGN Amgen still top obesity M&A candidate. They stated before “ all in “ although I sense different all in from $PFE Bourla”s
0 · Reply
hegdaom
hegdaom May. 10 at 4:49 AM
$CAPR An early win here legally and an approval creates a strong pathway to a $10 billion valuation with $RHHBY & $PFE as acquirers. $XBB $XBI
0 · Reply
BioRich
BioRich May. 7 at 11:55 AM
$ALT Here's one to spark MASSIVE discussion... $RHHBY just bought PathAI.... $750M deal. Run with this $ALT Nation. Cheers! $XBI
0 · Reply
GreenEnergy7B
GreenEnergy7B May. 7 at 10:49 AM
$ALT GLP1/Obesity/MASH M&A is heating up. Who will buy ALT first in phs3? https://www.cnbc.com/2026/05/06/novo-nordisk-ceo-mike-doustdar-ozempic-maker-looking-for-deals.html $NVO $PFE $MRK $RHHBY
0 · Reply
LabPsycho
LabPsycho May. 6 at 3:05 PM
$MAIA I am going to keep posting my idea on how to 5X THIO's potential market value until someone takes the baton and runs with it. My antibody ADC-THIO construct shown below based on my computational chemistry and molecular dynamic simulations, and the hypothesis / plausibility is supported by several peer reviewed articles and my own creative, scientifically sound input. In my earlier posts I also describe quick, easy, cost effective pilot studies one could do in a lab in one day to evaluate feasibility. Come on $REGN or $RHHBY - see the light.
1 · Reply
Quantumup
Quantumup May. 5 at 11:11 AM
Chardan🏁 $CLYM and said: We initiate coverage on Climb Bio with a Buy rating and a $22 price target. $RHHBY $VERA TVTX VRDN AMGN NVS AZN Here's what else Chardan had to say in its initiation report: https://x.com/Quantumup1/status/2051619926608085497?s=20
0 · Reply
DidYouReadThis
DidYouReadThis Apr. 30 at 5:28 PM
$OTLK Was anyone surprised by Norse 8? Was week 12 surprising? $REGN $RHHBY $COR
2 · Reply
Hooooooold
Hooooooold Apr. 27 at 10:01 PM
$NVO $RHHBY $MRK sureeee who has another pill that's approved , doing amazing rx numbers, safe and getting great patient results? Seems not Lilly. Who else and when will it be out?
0 · Reply
Brruh
Brruh Apr. 27 at 8:34 PM
$NVO the next 2 quarters is our last chance to get to 60. The best case scenario of foundayo keep crashing + cagri beats reta in the late trial + Mr headwinds sandbagging the earnings can get us there. If we will not see 60 this year, next year will be almost impossible with the entrance of new players to the glp1 market $RHHBY $MRK
1 · Reply
scotttrader213
scotttrader213 Apr. 23 at 3:40 PM
$RHHBY Many of Roche’s biggest drugs come from Genentech pipelines * Roughly a huge portion of Roche’s pharma innovation flows through Genentech * Genentech is a core competitive advantage vs other pharma giants
1 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 22 at 2:02 PM
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition $OTLC $AUTL $WVE $IOBTQ $RHHBY https://ibn.fm/4yuU5
0 · Reply
stu
stu Apr. 22 at 1:14 PM
$TGTX $RHHBY Fenebrutinib and deaths: "AAN26: Relapse rates for Roche's MS drug fenebrutinib overshadowed by lingering safety concerns." "Roche presented further positive efficacy results on its multiple sclerosis (MS) therapy hopeful fenebrutinib at the American Academy of Neurology (AAN) annual meeting on Tuesday, but the BTK inhibitor's safety profile remains a key focus, particularly an imbalance in deaths." " Data showed that the deaths occurred at different timepoints and had various causes, including infections — neuro Cryptococcosis gattii and pneumonia — complications of type 1 diabetes, serious bleeding, suicide, injuries from accident and death of unknown cause." https://firstwordpharma.com/story/7203815
2 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Apr. 22 at 12:21 AM
$KYTX x $RHHBY = EU GTM rocket 🚀 👉 Roche is a top-5 global pharma + oncology KING with unmatched reach 👉 Deep oncology + cell therapy focus = perfect fit for Kyverna pipeline 👉 150+ markets + global commercial engine ready to scale instantly 👉 Unique combo of diagnostics + pharma = precision medicine advantage (huge for autoimmune positioning) 👉 Proven partner mindset (BioNTech, MOMA, Chugai… they know how to scale biotech) 💡 Translation: Roche doesn’t just partner… they industrialize innovation globally If $KYTX wants serious EU GTM + credibility with payers & regulators…this is the Tier 1 door. Big pharma validation + EU scale = rerating catalyst 💲💲💲
0 · Reply
Thaigrlsrk
Thaigrlsrk Apr. 19 at 12:54 AM
$SRPT Jack Hall @Hall8Jack · Apr 17 I read the primary endpoint for this new $RHHBY trial is TTR instead of NSAA. If so, this seems like favorable treatment by the EMA. $SRPT Embark was stat sig on TTR. https://fiercepharma.com/pharma/roche-launch-another-elevidys-study-after-eu-rejection-duchenne-gene-therapy .
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Apr. 17 at 4:15 PM
$KYTX $GILD $KITE $BMY $RHHBY who will make the MOVE first? And who will be the last to join the party below 10$? Good Luck Ladies and Gentlemen 💲 💲💲
0 · Reply
IndyOne
IndyOne Apr. 16 at 4:45 PM
$MRNA Moderna is an absolute work horse. V940 clinical results for Melanoma and NSCLC (Non-Small Cell Lung Cancer). V940 platform expansion includes renal cell carcinoma and bladder cancer. CEO committed to 10%+ revenue growth 2026. TELLS: October 2025: "Deal of significant scope" in discussion, buyout or massive partnership. December 2025: Stéphane Bancel, Moderna CEO, sold his six-level home in Boston where he had lived for +12 years. January 2026: Moderna and Merck announced V940 results showed a 49% reduction in the risk of recurrence or death. Keytruda goes off patent soon, Merck can use Moderna's mRNA-4157 (also known as intismeran autogene) a first-of-its-kind, personalized mRNA cancer vaccine to extend Keytruda protection. February 2026: Patent litigation resolved. NO ROYALTIES! HUGE WIN. Moderna wanted the decks clear, they could have fought this longer like Pfizer & BioNtech. Partnership or buyout coming from $MRK $PFE $RHHBY or $GSK .
0 · Reply
scotttrader213
scotttrader213 Apr. 16 at 3:05 PM
$RHHBY announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics $SRPT for the muscle-wasting disorder. Duchenne muscular dystrophy, in an attempt to secure EU approval for the gene therapy.
1 · Reply